In a report released today, Gary Nachman from BMO Capital maintained a Buy rating on Aptinyx (APTX – Research Report), with a price target of $2.00. The company’s shares opened today at $0.31.
Nachman covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Horizon Therapeutics, and AbbVie. According to TipRanks, Nachman has an average return of -9.1% and a 40.76% success rate on recommended stocks.
Currently, the analyst consensus on Aptinyx is a Moderate Buy with an average price target of $1.67.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $3.76 and a one-year low of $0.20. Currently, Aptinyx has an average volume of 421.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.
